CNS Pharmaceuticals, Inc. (CNSP) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-04

Key Insights

Steve O'Loughlin, the Chief Financial Officer of CNS Pharmaceuticals, Inc., has been granted 9,500 restricted stock units (RSUs) that will vest over the next three years, aligning his interests with shareholders.
The vesting schedule of the RSUs, with 25% vesting at 6 months and 12 months and the remaining 50% vesting quarterly over the following 2 years, suggests a long-term commitment to the company.
Insider ownership by the CFO is a positive signal, indicating management's confidence in the company's future prospects.

Want the newest filings?

This analysis covers the filing from 2026-03-04. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-04

The reporting person, Eric Faulkner, was granted 9,500 restricted stock units as part of his compensation as the Chief Technology Officer of CNS Pharmaceuticals, Inc.
The restricted stock units vest over a 3-year period, with 25% vesting at 6 and 12 months, and the remaining 50% vesting in 12 quarterly installments, subject to Faulkner's continued employment.
This grant of equity-based compensation indicates that the company is incentivizing its technology leadership to remain with the organization and work towards its long-term success.

Filed: 2026-01-02

Rami Levin, the CEO and President of CNS Pharmaceuticals, Inc. (CNSP), has been granted 19,000 restricted stock units as part of his employment agreement, which vest over a 3-year period.
The restricted stock units were granted on 01/01/2026, indicating Levin's continued commitment to the company and alignment with shareholder interests.
The vesting schedule of the restricted stock units, with 25% vesting at 6 months, 25% at 12 months, and the remaining 50% vesting over 12 quarterly installments, suggests a focus on long-term performance and retention.

Other reports for CNS Pharmaceuticals, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.